natgillin/translations-raw huggingface dataset:
Pradaxa is a medicine which is used to treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occuring in the vein of your legs and lungs
Pradaxa je lijek koji se primjenjuje u liječenju krvnih ugrušaka u venama nogu i pluća te za sprječavanje ponovne pojave krvnih ugrušaka u venama nogu i pluća.
Pradaxa is available in packs containing 10 x 1, 30 x 1, 60 x 1 a multipack containing 3 packs of 60 x 1 hard capsules (180 hard capsules) or a multipack containing 2 packs of 50 x 1 hard capsules (100 hard capsules) in aluminium perforated unit dose blisters.
Pradaxa je dostupna u pakiranjima s 10 x 1, 30 x 1, 60 x 1 ili u višestrukom pakiranju s 3 pakiranja s 60 x 1 tvrdom kapsulom (180 tvrdih kapsula) ili u višestrukom pakiranju koje sadrži 2 pakiranja s 50 x 1 tvrdom kapsulom (100 tvrdih kapsula) u aluminijskim perforiranim blisterima djeljivim na jedinične doze.
Pradaxa is available in packs containing 10 x 1, 30 x 1, 60 x 1 capsules in aluminium perforated unit dose blisters.
Pradaxa je dostupna u pakiranjima s 10 x 1, 30 x 1, 60 x 1 kapsula u aluminijskim perforiranima blisterima djeljivim na jedinične doze.
Pradaxa is contraindicated in patients with severe renal impairment
Pradaxa je kontraindicirana kod bolesnika s teškim oštećenjem bubrega
Pradaxa is used for the following:
Pradaxa se koristi za sljedeće:
Pradaxa must also not be used in patients with serious liver problems or patients taking by mouth or injection the medicines ketoconazole and itraconazole (used for fungal infections), ciclosporin (a medicine used to reduce the activity of the immune system) or dronedarone (a medicine to treat a heart problem called atrial fibrillation).
Pradaxa se također ne smije koristiti u bolesnika s ozbiljnim problemima funkcije jetre ili u bolesnika koji uzimaju lijekove ketokonazol i itrakonazol (koristi se protiv gljivičnih infekcija), ciklosporin (lijek koji se koristi za smanjivanje djelovanja imunološkog sustava) ili dronedaron (lijek za liječenje srčanih problema naziva fibrilacija atrija).
Pradaxa must not be used in patients who have severely reduced kidney function, who are currently bleeding significantly or who have a condition putting them at significant risk of major bleeding.
Pradaxa se ne smije primjenjivati u bolesnika koji imaju ozbiljno smanjenje funkcije bubrega, onih sa značajnim krvarenjem ili koji su izloženi značajnom riziku od većeg krvarenja zbog svoje bolesti.
Pradaxa should be swallowed as a whole with a glass of water, to facilitate delivery to the stomach.
Pradaxa se treba progutati kao cijelovita kapsula s čašom vode kako bi se olakšalo njezino dospijevanje do želuca.
Pradaxa should be swallowed as a whole with a glass of water, to facilitate delivery to the stomach.
Pradaxa se treba progutati kao cijelovita kapsula s čašom vodom kako bi se olakšalo njezino dospijevanje do želuca.
Pradaxa should not be used in children and adolescents below 18 years old.
Pradaxa se ne smije primjenjivati u djece i adolescenata ispod 18 godina starosti.
Pradaxa treatment can be re-initiated 24 hours after administration of Praxabind (idarucizumab), if the patient is clinically stable and adequate haemostasis has been achieved.
Liječenje Pradaxom može se ponovno započeti 24 sata nakon primjene Praxbinda (idarucizumab), ako je bolesnik klinički stabilan te ako je postignuta odgovarajuća hemostaza.
Pradaxa treatment can be re-initiated 24 hours after administration of Praxbind (idarucizumab), if the patient is clinically stable and adequate haemostasis has been achieved.
Liječenje Pradaxom može se ponovno započeti 24 sata nakon primjene Praxbinda (idarucizumab) ako je bolesnik klinički stabilan te ako je postignuta odgovarajuća hemostaza.
Pradaxa treatment to parenteral anticoagulant
Prijelaz s liječenja Pradaxom na parenteralne antikoagulanse
Pradaxa treatment to parenteral anticoagulant
Prijelaz s Pradaxe na parenteralne antikoagulanse
Pradaxa treatment to Vitamin K antagonists (VKA)
Prijelaz s liječenja Pradaxom na antagoniste vitamina K (VKA)
Pradaxa was as effective as enoxaparin in preventing the formation of blood clots or death.
Lijek Pradaxa bio je jednako djelotvoran kao enoksaparin u sprječavanju stvaranja krvnih ugrušaka ili smrti.
Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation.
Primjenu Pradaxe potrebno je privremeno prekinuti zbog povećanog rizika od krvarenja tijekom ili kratko nakon operacije.
Pradaxa, which is taken by mouth, has the advantage of being more convenient for patients.
Prednost lijeka Pradaxa, koji se primjenjuje na usta, jest da je praktičniji za bolesnike.
Pradaxa® can be taken with or without food.
Pradaxa® se može uzimati sa ili bez hrane.
Pradaxa® Information for Healthcare Professionals
Pradaxa® Informacije za zdravstvene djelatnike
Pradaxa® Information for Patients
Pradaxa® Informacije za bolesnike
Pradaxa® is an oral anticoagulant acting by direct thrombin inhibition.
Pradaxa® je oralni antikoagulans koji djeluje putem direktne inhibicije trombina.
Pradaxa® is dialyzable.
Pradaxa® se može dijalizirati.
Pradaxa® makes your blood less “sticky”, prevents clot formation and reduces your risk of suffering from a stroke or other complications.
Pradaxa® čini krv manje “ljepljivom”, sprječava stvaranje ugrušaka i smanjuje rizik od dobivanja moždanog udara ili drugih komplikacija.
Prader-Willi syndrome
Prader Willijev sindrom
Prader-Willi syndrome (PWS), for improvement of growth and body composition.
Prader-Willijev sindrom (PWS) za poboljšanje rasta i oblikovanja tijela.
Pradofloxacin 120 mg
Pradofloksacin 120 mg
Pradofloxacin 15 mg
Pradofloksacin 15 mg
Pradofloxacin 25 mg
Pradofloksacin 25 mg
Pradofloxacin 25 mg/ml
Pradofloksacin 25 mg/ml
Pradofloxacin 60 mg
Pradofloksacin 60 mg
Pradofloxacin dose
Doza pradofloksacina (mg/kg bw)
Pradofloxacin dose (mg/kg bw)
Doza pradofloksacina (mg/kg tm)
Pradofloxacin has been shown to have no effects on fertility in breeding animals.
Pradofloksacin dokazano nema utjecaja na plodnost kod rasplodnih životinja.
Pradofloxacin has been shown to have no effects on fertility in breeding animals.
Za pradofloksacin je dokazano da nema utjecaj na plodnost kod rasplodnih životinja.
Pradofloxacin has been shown to have no effects on fertility in breeding animals.
Za pradofloksacin je dokazano da nema utjecaja na plodnost kod rasplodnih životinja.
Pradofloxacin has no effects on the developing cartilage of kittens of 6 weeks of age and older.
Pradofloksacin nema utjecaja na hrskavicu u razvoju kod mačića starih 6 tjedana i više.
Pradofloxacin induced eye malformations at foetal and maternal toxic dosages in rats.
Pradofloksacin je inducirao malformacije na očima u fetotoksičnoj i maternotoksičnoj dozi kod štakora.
Pradofloxacin induced eye malformations at foetal and maternal toxic doses in rats.
Pradofloksacin je inducirao malformacije na očima u fetotoksičnim i maternotoksičnim dozama kod štakora.
Pradofloxacin is cleared from the body at 0.28 l/h/kg.
Pradofloksaci je uklonjen iz tijela 0,28 l/h/kg.
Praluent 150 mg injection alirocumab
Praluent 150 mg injekcija alirokumab
Praluent 150 mg solution for injection in a pre-filled pen alirocumab
Praluent 150 mg otopina za injekciju u napunjenoj brizgalici alirokumab
Praluent 150 mg solution for injection in a pre-filled syringe alirocumab
Praluent 150 mg otopina za injekciju u napunjenoj štrcaljki alirokumab
Praluent 150 mg solution for injection in pre-filled pen alirocumab
Praluent 150 mg otopina za injekciju u napunjenoj brizgalici alirokumab
Praluent 150 mg solution for injection in pre-filled syringe alirocumab
Praluent 150 mg otopina za injekciju u napunjenoj štrcaljki alirokumab
Praluent 75 mg solution for injection in a pre-filled pen alirocumab
Praluent 75 mg otopina za injekciju u napunjenoj brizgalici alirokumab
Praluent 75 mg solution for injection in a pre-filled pen Praluent 150 mg solution for injection in a pre-filled pen
Praluent 75 mg otopina za injekciju u napunjenoj brizgalici Praluent 150 mg otopina za injekciju u napunjenoj brizgalici
Praluent 75 mg solution for injection in a pre-filled syringe Praluent 150 mg solution for injection in a pre-filled syringe
Praluent 75 mg otopina za injekciju u napunjenoj štrcaljki Praluent 150 mg otopina za injekciju u napunjenoj štrcaljki
Praluent 75 mg solution for injection in pre-filled pen alirocumab
Praluent 75 mg otopina za injekciju u napunjenoj brizgalici alirokumab
Praluent 75 mg solution for injection in pre-filled syringe alirocumab
Praluent 75 mg otopina za injekciju u napunjenoj štrcaljki alirokumab
Praluent contains the active substance alirocumab.
Praluent sadrži djelatnu tvar alirokumab.
Praluent has been studied in 10 main studies involving over 5,000 adult patients with hypercholesterolaemia (including patients with heterozygous familial disease) and mixed dyslipidaemia.
Praluent je ispitan u 10 glavnih ispitivanja koja su obuhvatila više od 5.000 odraslih bolesnika s hiperkolesterolemijom (uključujući bolesnike s heterozigotnom obiteljskom bolesti) i miješanom dislipidemijom.
Praluent is a clear, colourless to pale yellow solution for injection that comes in a pre-filled pen.
Praluent je bistra, bezbojna do blijedo žuta otopina za injekciju koja dolazi u napunjenoj brizgalici.
Praluent is a clear, colourless to pale yellow solution for injection that comes in a pre-filled syringe.
Praluent je bistra, bezbojna do blijedo žuta otopina za injekciju koja dolazi u napunjenoj štrcaljki.
Praluent is a medicine used to treat adults with primary hypercholesterolaemia (high blood cholesterol levels, in particular of the type ‘LDL-cholesterol’ or ‘bad’ cholesterol).
Praluent je lijek koji se koristi za liječenje odraslih osoba s primarnom hiperkolesterolemijom (visokom razinom kolesterola u krvi, posebice LDL kolesterola ili „lošeg” kolesterola).
Praluent is a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body).
Praluent je monoklonsko protutijelo (jedna vrsta specijaliziranog proteina oblikovanog tako da se pričvrsti za ciljnu tvar u tijelu).
Praluent is also used to treat mixed dyslipidaemia (abnormal levels of fats in blood, including high levels of LDL-cholesterol).
Praluent se također primjenjuje u terapiji miješane dislipidemije (abnormalne koncentracije masnoće u krvi, uključujući visoku razinu LDL kolesterola).
Praluent is to be used together with a low-fat diet, in the following ways:
Lijek Praluent treba primjenjivati s prehranom siromašnom masnoćama u sljedećim slučajevima:
Praluent should be used with caution in patients with severe renal impairment.
Praluent treba primjenjivati uz oprez u bolesnika s teškim oštećenjem bubrežne funkcije.
Pramipexole Accord
Pramipeksol Accord
Pramipexole Accord 0.088 mg
Pramipeksol Accord 0,088 mg
Pramipexole Accord 0.088 mg tablet
Pramipeksol Accord 0,088 mg tablete
Pramipexole Accord 0.088 mg tablets are white to off-white, round, flat faced, bevel edged, with inscription ‘I1’ on one side and plain on the other side.
Pramipeksol Accord 0,088 mg tablete su bijele do gotovo bijele, okrugle, plosnate, ukošenih rubova s oznakom "I1" na jednoj strani i bez oznaka na drugoj strani.
Pramipexole Accord 0.088 mg tablets Pramipexole
Pramipeksol Accord 0,088 mg tablete pramipeksol
Pramipexole Accord 0.18 mg
Pramipeksol Accord 0,18 mg
Pramipexole Accord 0.18 mg tablets are white to off-white, round, flat faced, bevel edged, with inscription ‘I’ and ‘2’ on either side of the breakline on one side and breakline on the other side.
Pramipeksol Accord 0,18 mg tablete su bijele do gotovo bijele, okrugle, plosnate, ukošenih rubova s oznakama „I” i „2” s dviju strana razdjelne crte na jednoj strani te s razdjelnom crtom na drugoj strani tablete.
Pramipexole Accord 0.18 mg tablets Pramipexole
Pramipeksol Accord 0,18 mg tablete pramipeksol
Pramipexole Accord 0.35 mg
Pramipeksol Accord 0,35 mg
Pramipexole Accord 0.35 mg tablets are white to off-white, round, flat faced, bevel edged, with inscription ‘I’ and ‘3’ on either side of the breakline on one side and breakline on the other side.
Pramipeksol Accord 0,035 mg tablete su bijele dogotovo bijele, okrugle, plosnate, ukošenih rubova s oznakama „I” i „3” s dviju strana razdjelne crte te s razdjelnom crtom na drugoj strani tablete.
Pramipexole Accord 0.35 mg tablets Pramipexole
Pramipeksol Accord 0,35 mg tablete pramipeksol
Pramipexole Accord 0.35 mg tablets Pramipexole
Pramipeksol Accord 0,7 mg tablete pramipeksol
Pramipexole Accord 0.7 mg
Pramipeksol Accord 0,7 mg
Pramipexole Accord 0.7 mg tablets are white to off-white, round, flat faced, bevel edged, with inscription ‘I’ and ‘4’ on either side of the breakline on one side and breakline on the other side..
Pramipeksol Accord 0,7 mg tablete su bijele dogotovo bijele, okrugle, plosnate, ukošenih rubova s oznakama „I” i „4” s dviju strana razdjelne crte te s razdjelnom crtom na drugoj strani tablete.
Pramipexole Accord 0.7 mg tablets Pramipexole
Pramipeksol Accord 0,7 mg tablete pramipeksol
Pramipexole Accord 1.1 mg
Pramipeksol Accord 1,1 mg
Pramipexole Accord 1.1 mg tablets are white to off-white, round, flat faced, bevel edged, with inscription ‘I’ and ‘5’ on either side of the breakline on one side and breakline on other side.
Pramipeksol Accord 1,1 mg tablete su bijele do gotovo bijele,, okrugle, plosnate,ukošenih rubova s oznakama „I” i „5” s dviju strana razdjelne crte te s razdjelnom crtom na drugoj strani tablete.
Pramipexole Accord 1.1 mg tablets Pramipexole
Pramipeksol Accord 1,1 mg tablete pramipeksol
Pramipexole Accord can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective.
Lijek Pramipeksol Accord može se primjenjivati kao monoterapija ili u kombinaciji s levodopom (drugi lijek za liječenje Parkinsonove bolesti) u bilo kojoj fazi bolesti, uključujući u uznapredovalim fazama u kojima levodopa gubi na djelotvornosti.
Pramipexole Accord has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s disease.
Pramipeksol Accord je povezan s pospanošću i epizodama iznenadnog usnivanja, osobito kod bolesnika s Parkinsonovom bolešću.
Pramipexole Accord is a ‘generic medicine’.
Lijek Pramipeksol Accord je „generički lijek”.
Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Pramipeksol Accord je indiciran za liječenje znakova i simptoma idiopatske Parkinsonove bolesti u odraslih, u obliku monoterapije (bez levodope) ili u kombinaciji s levodopom, tj. tijekom trajanja bolesti, pa sve do u uznapredovaloj fazi, kada učinak levodope jenjava ili postane nestalan te dolazi do fluktuacija u terapijskom učinku (učinak "kraja doze” i “on-off” razdoblja).
Pramipexole Accord is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population.
Primjena Pramipeksol Accorda se ne preporučuje u djece i adolescenata ispod 18 godina starosti jer njegova sigurnost i djelotvornost nisu ustanovljene za ovu populaciju.
Pramipexole Accord is not recommended for use in children or adolescents under 18 years.
Pramipeksol Accord se ne preporučuje za primjenu kod djece i adolescenata mlađih od 18 godina.
Pramipexole Accord is used to treat the symptoms of Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Lijek Pramipeksol Accord koristi se za liječenje simptoma Parkinsonove bolesti, progresivnog moždanog poremećaja koji uzrokuje tresavicu, usporene pokrete i ukočenost mišića.
Pramipexole Accord with food, drink and alcohol
Pramipeksol Accord s hranom,pićem i alkoholom
Pramipexole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson’s disease.
Liječenje pramipeksolom se povezuje s pojavom somnolencije i epizodama iznenadnog usnivanja, pogotovo u bolesnika s Parkinsonovom bolešću.
Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity.
Pramipeksol je agonist dopamina koji se s visokom selektivnošću i specifičnošću veže za D2 podskupinu dopaminskih receptora, od kojih poseban afinitet pokazuje za D3 receptore i ima potpuno intrinzičko djelovanje.
Pramipexole is associated with somnolence (8.6%) and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (0.1%). (See also section 4.4).
Pramipeksol je povezan sa somnolencijom (8,6%) te se manje često povezuje s pojavom prekomjerne dnevne somnolencije i epizodama iznenadnog usnivanja (0,1%) (također vidjeti dio 4.4).
Pramipexole is associated with somnolence (8.6%) and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (0.1%). (See also section 4.4).
Pramipeksol je povezan sa somnolencijom (8,6%) te se manje često povezuje s pojavom prekomjerne dnevne somnolencije i epizodama iznenadnog usnivanja (0,1%) (vidjeti također dio 4.4).
Pramipexole may be associated with libido disorders (increased or decreased).
Pramipeksol može biti povezan s poremećajima libida (pojačan ili smanjen).
Pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt).
Stoga je potrebno postupno smanjivati dozu pramipeksola, za 0,54 mg baze (0, 75 mg soli) dnevno, sve dok se ukupna dnevna doza ne snizi na 0,54 mg baze (0,75 mg soli).
Pramipexole shows linear kinetics and a small inter-patient variation of plasma levels.
Pramipeksol pokazuje linearnu kinetiku i malenu varijaciju vrijednosti u plazmi među bolesnicima.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira mozak na isti način kao i dopamin tako da bolesnici mogu kontrolirati svoje pokrete te imaju manje znakova i simptoma Parkinsonove bolesti poput tresavice, ukočenosti i usporavanja pokreta.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira mozak poput dopamina kako bi bolesnici mogli kontrolirati pokrete i imali manje znakova i simptoma Parkinsonove bolesti kao što su tresavica, ukočenost i usporenost pokreta.
Pramipexole Teva
Pramipeksol Teva
Pramipexole Teva 0.088 mg tablets are white, round tablets, embossed with "93" on one side and "P1" on the other side.
Pramipeksol Teva 0,088 mg tablete su bijele, okrugle tablete s utisnutom oznakom “93” na jednoj strani te “P1” na drugoj strani.
Pramipexole Teva 0.088 mg tablets EU/1/08/490/001
Pramipeksol Teva 0,088 mg tablete EU/1/08/490/001
Pramipexole Teva 0.088 mg tablets Pramipexole
Pramipeksol Teva 0,088 mg tablete pramipeksol
Pramipexole Teva 0.088 mg tablets Pramipexole Teva 0.18 mg tablets Pramipexole Teva 0.35 mg tablets Pramipexole Teva 0.7 mg tablets
Pramipeksol Teva 0,088 mg tablete Pramipeksol Teva 0,18 mg tablete Pramipeksol Teva 0,35 mg tablete Pramipeksol Teva 0,7 mg tablete
Pramipexole Teva 0.18 mg tablets are white round, scored tablets embossed with "P2" over "P2" on the scored side and "93" on the other side.
Pramipeksol Teva 0,18 mg tablete su bijele, okrugle tablete s utisnutom oznakom "P2" na svakoj polovici tablete na kojoj je razdjelna crta te s oznakom "93" na drugoj strani tablete.
Pramipexole Teva 0.18 mg tablets EU/1/08/490/005 EU/1/08/490/006 EU/1/08/490/007 EU/1/08/490/008 EU/1/08/490/019 EU/1/08/490/020
Pramipeksol Teva 0,18 mg tablete EU/1/08/490/005 EU/1/08/490/006 EU/1/08/490/007 EU/1/08/490/008 EU/1/08/490/019 EU/1/08/490/020
Pramipexole Teva 0.18 mg tablets Pramipexole
Pramipeksol Teva 0,18 mg tablete pramipeksol
Pramipexole Teva 0.35 mg tablets are white, oval, biconvex tablets, engraved with 9 vertical scoreline 3 on the scored side, and 8023 on the other side.
Pramipeksol Teva 0,35 mg tablete su bijele, ovalne, bikonveksne tablete s utisnutim 9 vertikalna razdjelna crta 3 na jednoj strani tablete, te oznakom 8023 na drugoj strani tablete.
Pramipexole Teva 0.35 mg tablets EU/1/08/490/009 EU/1/08/490/010 EU/1/08/490/011 EU/1/08/490/012 EU/1/08/490/021 EU/1/08/490/022
Pramipeksol Teva 0,35 mg tablete EU/1/08/490/009 EU/1/08/490/010 EU/1/08/490/011 EU/1/08/490/012 EU/1/08/490/021 EU/1/08/490/022
Pramipexole Teva 0.35 mg tablets Pramipexole
Pramipeksol Teva 0,35 mg tablete pramipeksol
Pramipexole Teva 0.7 mg
Pramipeksol Teva 0,7 mg
Pramipexole Teva 0.7 mg tablets are white, round, scored tablets embossed with "8024" over "8024" on the scored side and "93" on the other side.
Pramipeksol Teva 0,7 mg tablete su bijele, okrugle, tablete s utisnutom oznakom "8024" na svakoj polovici tablete na kojoj je razdjelna crta te s oznakom "93" na drugoj strani tablete.
Pramipexole Teva 0.7 mg tablets EU/1/08/490/013 EU/1/08/490/014 EU/1/08/490/015 EU/1/08/490/016 EU/1/08/490/023 EU/1/08/490/024
Pramipeksol Teva 0,7 mg tablete EU/1/08/490/013 EU/1/08/490/014 EU/1/08/490/015 EU/1/08/490/016 EU/1/08/490/023 EU/1/08/490/024
Pramipexole Teva 0.7 mg tablets Pramipexole
Pramipeksol Teva 0,7 mg tablete pramipeksol
Pramipexole Teva can cause hallucinations (seeing, hearing or feeling things that are not there).
Pramipeksol Teva može uzrokovati halucinacije (stanje da vidite, čujete ili osjetite stvari koje ne postoje).
Pramipexole Teva can have a major influence on the ability to drive and use machines.
Pramipeksol Teva može značajno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Pramipexole Teva contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Pramipeksol Teva sadrži djelatnu tvar pramipeksol i pripada skupini lijekova poznatih kao dopaminski agonisti koji stimuliraju dopaminske receptore u mozgu.
Pramipexole Teva has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s disease.
Pramipeksol Teva je povezan s pospanosti i epizodama iznanadnog padanja u san, osobito kod bolesnika s Parkinsonovom bolešću.
Pramipexole Teva is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Pramipeksol Teva je indiciran u odraslih za liječenje znakova i simptoma idiopatske Parkinsonove bolesti u odraslih, u obliku monoterapije (bez levodope) ili u kombinaciji s levodopom, tj. tijekom trajanja bolesti pa sve do uznapredovale faze, kada učinak levodope jenjava ili postane nestalan te dolazi do fluktuacija u terapijskom učinku (učinak "kraja doze” i “on-off” razdoblja).
Pramipexole Teva is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population.
Primjena Pramipeksola Teva se ne preporučuje u djece i adolescenata u dobi do 18 godina, jer njegova sigurnost i djelotvornost nije ustanovljena za ovu populaciju.
Pramipexole Teva is not recommended for use in children or adolescents under 18 years.
Pramipeksol Teva se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
Pramipexole Teva is used to treat the symptoms of primary Parkinson’s disease in adults.
Pramipeksol Teva se koristi u liječenju simptoma primarne Parkinsonove bolesti u odraslih.